高盛发表研究报告指，再鼎医药(09688.HK) (ZLAB.US) 2024年第四季销售表现符合预期，收入按年增长66%至1.085亿美元，符合该行预期的1.08亿美元，各项产品收入表现均符合高盛预测，相信公司去年优化商业团队所带来的短期影响已消散，预测2025财年艾加莫德(Efgartigimod)收入将达到10亿元人民币，重申2025年是再鼎医药发展里程碑年，亏损预期将持续收窄，预计至今年第四季可实现盈利，关注bemarituzumab、TIVDAK及Optune等产品的新药上市申请进展，给予“买入”评级。
高盛将再鼎医药2025至2026年每股亏损预测从原先各2美元及0.4美元，调整至每股亏损各1.6美元及0.3美元，H股目标价从40.4港元上调至42.01港元。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-03 12:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.